

Boehringer Ingelheim takes cancer therapies to China in partnership with Sino Biopharma

10 April 2024 | News

Joint collaboration to develop and commercialise Boehringer Ingelheim's oncology pipeline in mainland China



Sino Biopharmaceutical Group has entered into a strategic partnership with Germany-headquartered Boehringer Ingelheim to bring Boehringer Ingelheim's innovative cancer therapies to the market in mainland China.

Under the agreement, Sino Biopharma and Boehringer Ingelheim will collaborate to jointly develop and commercialise Boehringer Ingelheim's oncology pipeline in mainland China. The strategic partnership covers multiple assets under clinical development by Boehringer Ingelheim, including three assets brigimadlin, zongertinib, and BI 764532, and multiple early-stage assets.

The companies will join efforts to bring these oncology products to patients in mainland China, with the Sino consolidating the revenue for the products in China.

Introduction of major assets under clinical development:

Brigimadlin is a mouse double minute 2 (MDM2)-p53 antagonist which has advanced into the pivotal trial for the treatment of dedifferentiated liposarcoma (DDLPS) and is being investigated for other cancers such as biliary tract cancer (BTC), non-small cell lung cancer (NSCLC), pancreatic cancer and other tumors with MDM2 amplifications.

Zongertinib is a selective human epidermal growth factor receptor 2 (HER2) inhibitor that covalently binds to the tyrosine kinase domain (TKD) of both wild type and mutated HER2 receptors, including those with an exon 20 mutation. Improved selectivity of a HER2 tyrosine kinase inhibitor (TKI) may result in better tolerability and efficacy.

BI 764532 is a delta-like canonical Notch ligand 3/cluster of differentiation 3 (DLL3/CD3) bispecific T-cell engager, which is currently in Phase II clinical study investigating for the treatment of small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).